Safety and Efficacy Study of Ambrisentan in Subjects With Pulmonary Hypertension

Completed · Phase 3

Conditions studied: Pulmonary Hypertension

In brief

The primary objective of this study was to evaluate the safety and efficacy of ambrisentan in a broad population of participants with pulmonary hypertension (PH). Secondary objectives of this study were to evaluate the effects of ambrisentan on other clinical measures of pulmonary arterial hypertension (PAH), long-term treatment success, and survival.

Key facts

Study ID
NCT00380068
Run by
Gilead Sciences
People needed
224
Starts
2006-08-01
Expected to finish
2009-05-01
Last updated by the study team
2012-04-05

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.